Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print RSS Feed

Financial Report: Merck



Published February 1, 2013
Merck
 
4QRevenue: $11.7 billion (-5%)

4Q Earnings: $1.4 billion (-7%)

YTD Revenues: $47.3 billion (-2%)

YTD Earnings: $6.7 billion (+6%)

Comments: Pharmaceutical sales were down 6% to $10.1 billion, including a 1% percent negative impact due to foreign exchange. Singulair sales were down 67% to $480 million. Cozaar/Hyzaar sales were down 26% to $315 million. Januvia sales were $1.1 billion in the quarter, up 18%. Zetia sales were $676 million, up 6%. Remicade sales were up 8% to $549 million. Janumet sales were up 17% to $452 million. Gardasil sales were up 61% to $442 million. Merck Animal Health sales totaled $898 million for the quarter, up 3%. Consumer Care sales were $395 million, up 9%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On